Life Sciences Automation Market Size, Share, Growth, and Industry Analysis, By Type (DCS, SCADA, PLC, MES), By Application (Medical Treatment, Others), Regional Insights and Forecast to 2035

•   
•   
  

  Download Free Sample to learn more about this report

    

LIFE SCIENCES AUTOMATION MARKET OVERVIEW

The global Life Sciences Automation Market size estimated at USD 1.45 billion in 2026 and is projected to reach USD 2.23 billion by 2035, growing at a CAGR of 4.91% from 2026 to 2035.

The Life Sciences Automation Market is expanding rapidly as pharmaceutical, biotechnology, and clinical laboratories adopt automated systems to improve precision, productivity, and regulatory compliance. More than 72% of pharmaceutical manufacturing facilities worldwide utilize some form of industrial automation, while over 68% of advanced research laboratories have integrated robotic sample handling systems. Automated laboratory workflows reduce manual processing time by nearly 45% and improve experiment reproducibility by approximately 38%. Digital integration across production, testing, and quality assurance continues to strengthen demand for Distributed Control Systems (DCS), Manufacturing Execution Systems (MES), Programmable Logic Controllers (PLC), and Supervisory Control and Data Acquisition (SCADA) solutions throughout the life sciences automation market.

The United States represents the largest national market for life sciences automation due to its extensive pharmaceutical manufacturing infrastructure and biotechnology research ecosystem. More than 5,700 pharmaceutical manufacturing establishments operate across the country, while over 3,000 biotechnology companies conduct advanced research and production activities. Approximately 76% of FDA-approved pharmaceutical manufacturing facilities employ automated quality monitoring systems. Robotic laboratory automation has increased by 41% across major research institutions since 2020, and automated manufacturing platforms now support nearly 69% of large-scale biologics production facilities, strengthening the country's leadership in life sciences automation technologies.

KEY FINDINGS

LATEST TRENDS

Automation technologies are transforming pharmaceutical manufacturing and laboratory operations through intelligent digital integration, robotics, artificial intelligence, and industrial connectivity. More than 67% of newly established pharmaceutical production facilities now deploy integrated Manufacturing Execution Systems connected with SCADA and PLC platforms for continuous process monitoring. Robotic sample preparation systems have improved laboratory throughput by 43%, while automated liquid handling technologies have reduced experimental errors by 37%. AI-assisted quality inspection systems identify production deviations with accuracy exceeding 95%, supporting faster product validation.

Digital twin technology continues gaining momentum, with approximately 29% of large pharmaceutical manufacturers utilizing virtual production models for equipment optimization and predictive maintenance. Cloud-connected automation platforms are implemented by 55% of advanced biotechnology facilities, enabling secure real-time monitoring across multiple production sites. Automated environmental monitoring systems reduce contamination incidents by nearly 32%, while smart sensors improve process visibility by 48%. Cybersecurity investments protecting industrial automation networks have increased by 35% as connected manufacturing expands.

MARKET DYNAMICS

Driver

Rising demand for pharmaceutical manufacturing automation.

The increasing production of pharmaceuticals, biologics, vaccines, and personalized medicines is the primary driver supporting the Life Sciences Automation Market. Approximately 73% of pharmaceutical manufacturers have upgraded production lines with automated process control technologies to improve product consistency and regulatory compliance. Automated filling systems reduce production errors by 41%, while robotic packaging solutions improve operational efficiency by 36%. More than 65% of biologics manufacturing facilities utilize advanced MES platforms for production tracking and batch documentation.

Restraint

High implementation costs and system integration complexity.

Despite significant benefits, automation deployment requires substantial capital investment and technical expertise. Nearly 46% of small pharmaceutical companies delay automation projects because of equipment installation expenses. Around 38% of manufacturers report challenges integrating modern automation with legacy production infrastructure. Staff training programs require approximately 120 hours for advanced automation platforms, increasing implementation timelines. Software validation procedures may extend project completion by 6 months under regulated manufacturing environments.

Growth in personalized medicine and biologics manufacturing

Opportunity

Personalized medicine and advanced biologic therapies create substantial opportunities for automation providers. More than 19,000 clinical studies involving precision medicine technologies are currently active worldwide, increasing demand for automated laboratory processing.

Automated cell culture platforms improve production consistency by 39%, while robotic analytical systems reduce laboratory turnaround time by 34%. Approximately 58% of new biologics manufacturing facilities incorporate modular automation architectures supporting flexible production.

Rising cybersecurity risks and workforce shortages

Challenge

The increasing digitalization of pharmaceutical manufacturing introduces new cybersecurity and workforce challenges. Approximately 52% of automation networks now connect directly with enterprise information systems, increasing exposure to cyber threats.

Around 43% of pharmaceutical companies report difficulties recruiting automation engineers with expertise in robotics, industrial software, and data analytics. Automated production facilities require continuous software validation, security monitoring, and equipment maintenance to ensure regulatory compliance.

•   
•   
  

  Download Free Sample to learn more about this report

    

LIFE SCIENCES AUTOMATION MARKET SEGMENTATION

By Type

• DCS: Distributed Control Systems represent approximately 18% of the Life Sciences Automation Market and remain important for large pharmaceutical manufacturing facilities requiring continuous process control. More than 61% of vaccine production plants employ DCS platforms to monitor temperature, pressure, and chemical processing variables simultaneously. Modern DCS solutions support over 100,000 input/output signals within integrated production environments while maintaining system availability exceeding 99.9%.

• SCADA: SCADA systems account for nearly 23% of automation deployments across the life sciences sector. Approximately 66% of pharmaceutical production facilities utilize SCADA software for centralized monitoring of manufacturing operations. These systems provide real-time visualization of equipment status, environmental conditions, and process performance across multiple production areas. Automated data acquisition improves operational visibility by 44%, while centralized control reduces production interruptions by 31%. Integration with industrial sensors allows continuous monitoring of humidity, pressure, cleanroom conditions, and utility systems essential for regulatory compliance.

• PLC: Programmable Logic Controllers hold approximately 28% of the Life Sciences Automation Market because of their flexibility, reliability, and compatibility with industrial equipment. More than 78% of pharmaceutical packaging lines utilize PLC systems for automated conveyor operation, labeling, filling, and inspection processes. High-speed PLC controllers execute thousands of logic operations every second while maintaining equipment synchronization across production lines. Automated fault detection reduces maintenance downtime by 34%, and PLC-based production control improves equipment utilization by 29%.

• MES: Manufacturing Execution Systems represent the largest technology segment with approximately 31% market share. Around 74% of newly automated pharmaceutical manufacturing facilities deploy MES platforms to manage production scheduling, electronic batch records, quality documentation, and regulatory reporting. MES implementation reduces documentation errors by 46% while shortening batch release times by 24%. Digital production records improve traceability across every manufacturing stage and support compliance with international pharmaceutical quality standards.

By Application

• Medical Treatment: Medical Treatment accounts for approximately 71% of the Life Sciences Automation Market due to extensive automation across pharmaceutical manufacturing, biologics production, vaccine processing, and hospital laboratory operations. More than 80% of high-volume pharmaceutical production facilities utilize automated inspection systems to improve product consistency and reduce manual intervention. Automated laboratory analyzers process thousands of diagnostic samples daily with accuracy exceeding 98%.

• Others: The Others segment contributes approximately 29% of the Life Sciences Automation Market and includes biotechnology research, contract research organizations, academic laboratories, environmental testing, food safety laboratories, and forensic science facilities. More than 59% of biotechnology research centers employ robotic liquid handling systems for high-throughput screening applications. Automated laboratory workflows improve sample processing capacity by 47%, while digital laboratory management systems reduce documentation time by 33%.

•   
•   
  Download Free Sample to learn more about this report

    

LIFE SCIENCES AUTOMATION MARKET REGIONAL INSIGHTS

• North America

North America leads the Life Sciences Automation Market with an estimated 39% market share, supported by its concentration of pharmaceutical manufacturers, biotechnology firms, contract research organizations, and advanced medical laboratories. The region has more than 6,000 life sciences manufacturing and research facilities using automated production systems.

Approximately 78% of large pharmaceutical production plants operate with integrated Manufacturing Execution Systems (MES), while 74% utilize advanced SCADA platforms for real-time monitoring and quality assurance. The United States dominates regional demand because of its strong pharmaceutical manufacturing ecosystem and continuous investment in biologics, vaccines, and precision medicine.

• Europe

Europe represents approximately 28% of the Life Sciences Automation Market, supported by strong pharmaceutical exports, biotechnology innovation, and strict regulatory standards governing manufacturing quality. More than 4,500 pharmaceutical production facilities across the region utilize industrial automation technologies.

Approximately 72% of pharmaceutical manufacturers have implemented automated quality control systems to strengthen compliance with international manufacturing standards. Germany remains Europe's largest automation hub due to its highly developed pharmaceutical and industrial engineering sectors. More than 68% of pharmaceutical production plants employ advanced PLC and DCS technologies for continuous manufacturing operations.

• Asia-Pacific

Asia-Pacific accounts for approximately 25% of the Life Sciences Automation Market and remains the fastest expanding regional manufacturing center due to pharmaceutical production growth, biotechnology investment, and government-supported healthcare modernization. More than 8,000 pharmaceutical manufacturing facilities operate throughout the region, with automation adoption increasing steadily across production and laboratory environments.

China leads regional automation deployment through large-scale pharmaceutical manufacturing and industrial digitalization initiatives. Approximately 69% of newly established pharmaceutical production plants incorporate MES and PLC systems for automated manufacturing control. Automated packaging lines have increased production efficiency by 38%, while robotic inspection systems improve product quality verification by 42%.

• Middle East & Africa

The Middle East & Africa accounts for approximately 8% of the Life Sciences Automation Market, supported by healthcare infrastructure development, pharmaceutical manufacturing expansion, and laboratory modernization initiatives. More than 900 pharmaceutical manufacturing facilities operate across the region, with automation investments increasing to strengthen domestic medicine production and reduce import dependence.

Saudi Arabia continues investing in pharmaceutical localization programs, where approximately 54% of modern manufacturing facilities utilize automated production monitoring systems. Robotic packaging technologies improve operational productivity by 29%, while digital quality management systems reduce documentation errors by 33%.

LIST OF TOP LIFE SCIENCES AUTOMATION COMPANIES

• OMRON Corp.
• Honeywell International Inc.
• Parker-Hannifin Corp.
• Yokogawa Electric Corp.
• Emerson Electric Co.
• Siemens AG
• Mitsubishi Electric Corp.
• Rockwell Automation Inc.
• Schneider Electric SE
• ABB Ltd.

List Of Top 2 Companies Market Share

• Siemens AG – Approximately 16% market share, supported by comprehensive automation platforms, MES integration, pharmaceutical digitalization solutions, and extensive deployment across global life sciences manufacturing facilities.
• Rockwell Automation Inc. – Approximately 13% market share, driven by advanced PLC, MES, industrial software, smart manufacturing technologies, and strong adoption across pharmaceutical, biotechnology, and laboratory automation applications.

INVESTMENT ANALYSIS AND OPPORTUNITIES

Investment activity within the Life Sciences Automation Market continues to accelerate as pharmaceutical manufacturers modernize production facilities and laboratories. Approximately 71% of large pharmaceutical companies increased capital allocation toward automation technologies during facility expansion projects. More than 65% of biotechnology manufacturers prioritize intelligent production systems supporting flexible manufacturing and digital quality assurance. Investments in robotic laboratory automation have increased sample processing efficiency by 46%, while automated production lines reduce operational downtime by 32%.

Contract development and manufacturing organizations are expanding automated manufacturing capacity to meet rising pharmaceutical outsourcing demand. Approximately 58% of newly commissioned biologics facilities include modular automation architectures supporting scalable production. Artificial intelligence integration into manufacturing operations improves predictive maintenance accuracy by 41%, reducing unexpected equipment failures. Cloud-based manufacturing platforms are implemented by 55% of new facilities to enable centralized monitoring and production analytics.

NEW PRODUCT DEVELOPMENT

Manufacturers continue introducing advanced automation technologies designed to improve pharmaceutical manufacturing efficiency, laboratory productivity, and regulatory compliance. Approximately 57% of newly launched automation platforms integrate artificial intelligence for predictive process optimization and equipment diagnostics. Modern MES software includes real-time production dashboards capable of monitoring more than 10,000 manufacturing variables simultaneously, strengthening operational transparency.

Robotic laboratory automation remains a major innovation area. New liquid handling systems improve dispensing precision by 99%, while automated sample preparation platforms increase laboratory throughput by 45%. Vision-based inspection technologies detect packaging defects with accuracy exceeding 98%, reducing manual quality control requirements. Smart collaborative robots are increasingly deployed for pharmaceutical packaging and material handling, improving workplace safety and production flexibility.

FIVE RECENT DEVELOPMENTS (2023-2025)

• January 2023: Siemens AG introduced an enhanced Opcenter manufacturing execution platform for the life sciences automation market, strengthening electronic batch records, digital quality management, and pharmaceutical production traceability. The update integrated cloud connectivity, advanced analytics, and regulatory compliance features, enabling manufacturers to improve production visibility, accelerate batch release processes, and support highly automated pharmaceutical manufacturing operations.
• May 2023: Rockwell Automation Inc. announced the acquisition of Verve Industrial Protection, expanding its industrial cybersecurity capabilities for automated pharmaceutical and biotechnology facilities. The acquisition enhanced protection for operational technology environments, helping life sciences manufacturers secure connected automation systems, reduce cyber risks, and strengthen compliance across digitally integrated production and laboratory operations.
• March 2024: ABB Ltd. launched new OmniCore™ robotic controllers for industrial automation applications, including pharmaceutical manufacturing and laboratory automation. The platform delivered faster motion control, improved precision, reduced energy consumption, and simplified integration with robotic inspection, packaging, and material-handling systems, supporting higher productivity and flexible manufacturing within life sciences facilities.
• September 2024: Schneider Electric SE unveiled expanded industrial automation solutions combining EcoStruxure software, SCADA, and Manufacturing Execution System technologies for regulated pharmaceutical manufacturing. The initiative focused on real-time production monitoring, digital quality documentation, predictive maintenance, and sustainability improvements, enabling life sciences manufacturers to optimize operational efficiency while maintaining stringent regulatory compliance.
• February 2025: Honeywell International Inc. introduced advanced AI-enabled digital automation capabilities within its industrial software portfolio for pharmaceutical manufacturing. The solution combined predictive analytics, connected asset performance monitoring, and intelligent process optimization to improve production reliability, minimize equipment downtime, and strengthen data-driven decision-making across life sciences automation environments.

LIFE SCIENCES AUTOMATION MARKET REPORT COVERAGE

The Life Sciences Automation Market report provides detailed analysis of automation technologies, industrial software, production systems, laboratory robotics, competitive positioning, regional performance, and emerging technological developments. The study evaluates automation adoption across pharmaceutical manufacturing, biotechnology production, laboratory research, diagnostics, and related healthcare industries. Market segmentation includes DCS, SCADA, PLC, and MES technologies together with Medical Treatment and Other application areas.

The report analyzes manufacturing digitalization trends, artificial intelligence integration, robotic automation, industrial connectivity, cybersecurity requirements, and regulatory compliance affecting market expansion. Regional assessment covers North America, Europe, Asia-Pacific, and the Middle East & Africa while highlighting automation adoption, manufacturing capacity, biotechnology investments, and technological modernization.